Roche, Bristol-Myers, Merck drugs aim at lung cancer
This article was originally published in Scrip
Executive Summary
A new class of experimental drugs shown to shrink tumors by unleashing the immune system are beginning to attract notice for one of the greatest unmet needs in oncology: treatment of lung cancer.